Payment of Cash Dividend

Beximco Pharmaceuticals Ltd

25 January 2024

 

25 January 2024

BEXIMCO PHARMACEUTICALS LIMITED

Payment of Cash Dividend

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the 35% cash dividend of the nominal value per ordinary share/GDR (Taka 3.50 per ordinary share/GDR) for the year ended 30 June 2023, which was approved in the Annual General Meeting ("AGM") held on 28 December 2023, has been deposited with the custodian bank (HSBC) in Dhaka on 24 January 2024 for onward credit to respective GDR holders' accounts.

For any queries regarding the credit of dividend to respective accounts of holders of GDRs, please contact the Depository (The Bank of New York Mellon) representative, Mr. Vinu Kurian, at [e-mail].

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer Tel: [phone], Ext. 20111 Mohammad Ali Nawaz, Chief Financial Officer Tel: [phone], Ext. 20030

SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: [phone] / 3555

SP Angel Corporate Finance LLP (Broker) Matthew Johnson Tel: [phone]

FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

 

END